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Abstract (<=200 words) 10 
The antibody seroprevalence of young stock can be a useful indicator of recent or current infection 11 
in a herd. We examine the factors that contribute to the assessment of herd exposure to disease, via 12 
spot testing for antibody, using bovine viral diarrhoea virus (BVDv) as an example. 13 
A statistical distribution of seroprevalences for BVDv in beef herds identified three groups of herds: 14 
low, intermediate and high within-herd BVDv antibody seroprevalence. We tested two assumptions 15 
–the intermediate seroprevalence group of herds is assumed to be negative for BVDv at the herd 16 
level and alternatively if this group is assumed to be positive.  17 
We found that: 18 
The herd-level sensitivity and specificity are sensitive to the assumption regarding the herds with 19 
intermediate seroprevalence 20 
If an appropriate cut-point is chosen, reducing the sample size from ten to five does not produce 21 
a large drop in herd-level test performance 22 
Increasing the cut-point may be valuable at the outset of an eradication programme 23 
Increasing the sample size  and decreasing the cut-point is advantageous towards the end of an 24 
eradication programme, to minimise the risk of positive herds being misclassified 25 
The framework presented here illustrates how seroprevalence screening may be understood and 26 
assessed. 27 
Keywords: sample size; cut-point; seroprevalence; BVDv; herd-level test sensitivity and specificity 28 
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Introduction 30 
For most infectious agents, antibodies measured in animals by an ELISA test provide information 31 
about the recent or historic exposure of those animals to the infectious agent. The prevalence of 32 
animals with high antibody levels (i.e., antibody seroprevalence) may thus be used to identify herds 33 
that have been recently or currently are being exposed to the infectious agent. This principle has 34 
been employed in the screening of herds for infectious diseases, such as bovine viral diarrhoea virus 35 
(BVDv) in cattle. 36 
BVDv is the infectious agent of a serious cattle disease of economic importance 1,2. BVDv is amenable 37 
to eradication at a national level if suitable testing and management in response to testing are put 38 
into action 3,4. It is possible to test directly for antigen to BVDv amongst individual animals but, if 39 
missed, an infectious animal can cause serious break down in status for the herd and result in 40 
further cycles of infection. An alternative method of identifying BVDv-infected herds involves the 41 
screening of animals for antibodies and the use of screening results as an indicator of virus 42 
circulating in the herd. For this primary screen based on antibodies it is common to screen young 43 
stock since their antibody levels are indicative of recent infection and it is the recent status of the 44 
herd which is typically of most interest 5. If a herd is deemed to be BVDv-positive (i.e., infected) on 45 
the basis of the detection of antibody-positive animals, a subsequent and more extensive search for 46 
antigen-positive (and potentially infectious) animals within the herd typically will be conducted.  A 47 
particular aim of such subsequent screening is the identification of persistently infected (“PI”) 48 
animals, which are epidemiologically important for the continued spread of disease 6,7. 49 
Using the presence of antibody-positive animals to identify infected herds is dependent upon several 50 
factors. Levels of within-herd antibody seroprevalence have been found to vary across populations 51 
of herds  5,8.  The variation in seroprevalence amongst herds that are truly BVDv-positive as well as 52 
among those that are truly BVDv-negative (i.e. not infected) will impact the results of a screening 53 
test. Among the other factors that will affect the performance of a screening test are the following: 54 
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• The sensitivity and specificity of the antibody test at the level of the individual animal; 55 
• The number of animals to be tested or sampled; and 56 
• The use of an appropriate cut-point or threshold for the number of test-positive animals in 57 
the sample at which the herd (or flock) is deemed positive. 58 
Together, these factors contribute to the specificity and sensitivity of the screening test at the level 59 
of the whole herd. 60 
Screening programmes for BVDv which utilise testing for antibodies in individual sera from young 61 
stock vary in the number of animals they require to be tested and in the cut-point , i.e., the number 62 
of seropositive animals which must be detected in the sample in order for the herd to be deemed 63 
positive. For example, the first mandatory testing stage of the Scottish eradication scheme 9 required 64 
five or ten young animals to be tested per management group depending on the age of the young 65 
stock with an implicit cut-point of one positive animal albeit with scope for reinterpretation by the 66 
veterinarian in the case of low numbers of animals with low or inconclusive antibody levels10. 67 
 68 
Thus the detection of even a single antibody seropositive animal in the sample was sufficient for the 69 
herd to be deemed positive for BVDv. In the eradication programme proposed for the Netherlands 70 
an initial screening of five young stock leads to additional testing if two or more tested animals are 71 
found to be antibody positive (Pers. Comm. Duijn, L. van 8/6/17). 72 
. 73 
As noted above, the within-herd BVDv antibody seroprevalence varies among herds. The statistical 74 
distribution of seroprevalence amongst young stock is generally U-shaped with a large proportion of 75 
herds with zero or close to zero seroprevalence and a large proportion with close to 100% 76 
seroprevalence 5. However, there is also evidence of a middle group or class of herds with 77 
intermediate seroprevalence (Figure 1) 8,11,12. It is not clear whether herds in this group are truly 78 
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BVDv-positive, BVDv-negative or a mix of both. How herds in this middle group are considered has 79 
implications for BVDv screening. In this paper we estimate the herd-level sensitivity and specificity of 80 
screening tests under various conditions, considering the range of within-herd BVDv antibody 81 
seroprevalence levels, different numbers of animals tested and different cut-points for the threshold 82 
above which a herd is deemed positive. Our objective is to provide quantitative evidence for those 83 
designing schemes of the herd-level test performance of young stock screening for BVDv. An 84 
additional objective is to provide policy implications that vary between the outset of an eradication 85 
scheme (when herd-level prevalence is high) and the latter stages of an eradication scheme (when 86 
false negatives are costly to the eradication scheme).  We also consider the importance of the 87 
middle group and how it may affect the interpretation of the results of screening for antibodies in 88 
young stock. 89 
 90 
  91 
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Results 92 
Results of test performance at the herd-level are presented for the following combination of 93 
scenarios (Figure 2): 94 
• Treatment of herds with intermediate levels of antibody seroprevalence as either BVDv 95 
negative or positive;  96 
• Testing of five or ten animals; and  97 
• Use of a cut-point or threshold (i.e. the number of positive animals at, or above which, the 98 
herd is declared positive) of different numbers of animals. 99 
From results illustrated in Figure 2, we note that the herd-level sensitivity drops and the herd-level 100 
specificity increases as the cut-point number of animals increases.  It is also clear that the sensitivity 101 
is much higher and specificity lower if the group of herds with intermediate seroprevalence in the 102 
original distribution is considered negative rather than positive. The designation of the group of 103 
herds with intermediate levels of seroprevalence is very important in deciding the optimum cut-104 
point. If this group is considered positive, then with a sample size of ten the optimum cut-point 105 
arguably is two positive animals.  By contrast, if this group is considered negative, then the optimum 106 
cut-point is arguably six to achieve both high sensitivity and specificity. There is a similar pattern 107 
when considering a sample size of five animals. The optimum cut-point appears to be one positive in 108 
the case of the middle component being positive and three positives from a sample of five in the 109 
case of the middle component being negative. 110 
Table 1 provides the herd-level performance estimates for a testing regime within a recommended 111 
control programme. Table 2 provides the overall probability of a false negative, the overall 112 
probability of a false positive, positive predictive value and negative predictive value under the 113 
eradication scheme in the Netherlands plus the consequences of reducing the cut-point r of 114 
seropositive animals from two to one. 115 
7 
 
The “false negative rate” is the probability that a truly positive herd tests negative (that is, the 116 
numerator is the number of truly positive herds which test negative, and the denominator is the 117 
number of truly positive herds) 13. Possibly of greater interest to the policy maker is the probability 118 
that any herd randomly selected from a population of herds is truly positive and tests negative (the 119 
numerator is unchanged, but the denominator in this case is the total number of herds). Here we 120 
use the term “overall probability of a false negative” to distinguish this value from the false negative 121 
rate. The overall probability of a false negative is simply the true herd-level prevalence multiplied by 122 
the false negative rate. 123 
The overall probability of a false negative naturally increases linearly with herd-level prevalence 124 
(Figures 3 & 4). It is noticeable that by dropping the cut-point from two (Figure 3) to one (Figure 5, 125 
Table 2) the overall probability of a false negative is decreased substantially. For a given cut-point, 126 
increasing the number of animals tested lowers the overall probability of a false negative (Figures 2, 127 
3 & 4).128 
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We illustrate the consequences of our assumption for the status of the intermediate seroprevalence 129 
group for a scenario provided within the Dutch eradication scheme in which the number of animals 130 
tested is five and the cut-point is two (Table 1). This demonstrates how much the sensitivity and 131 
specificity of the test depends on this assumption with the sensitivity changing from 75% to 100% 132 
under the two assumptions. 133 
In Table 2 we present the overall probability of false negatives and false positives. False negatives in 134 
particular are undesirable towards the latter stages of eradication when most herds and most 135 
animals are susceptible and therefore at risk of infection through the failure to identify a positive 136 
herd. We see that even though the overall probability of a false negative is lower when the 137 
prevalence is lower, the overall probability of a false negative can be reduced further by lowering 138 
the cut-point to one.  139 
 140 
In Figures 3 and 4 we see the linear relationship between the herd level prevalence and the overall 141 
median probability of false negatives. We see that as the number of animals tested goes up for a 142 
fixed cut-point the overall probability of a false negative goes down. Finally we note that for any 143 
particular number of animals tested, if the cut point is reduced to one then the over all probability of 144 
a false negativedecreases. 145 
 146 
We do not present figures for the median overall probability of false negatives when herds with 147 
intermediate within-herd seroprevalence are treated as negative because in that situation the 148 
median rate of false negatives is zero for both a cut-point of one or two positive animals. 149 
  150 
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Discussion 151 
For most infectious agents, antibodies measured in animals by an ELISA test provide information 152 
about the recent or historic exposure of those animals to the infectious agent. The prevalence of 153 
animals with high antibody levels (i.e., seroprevalence) may thus be used to identify herds that have 154 
been or are being exposed to high levels of the infectious agent, provided that estimates of 155 
seroprevalence can be interpreted as a herd-level result. In this study we employ the example of 156 
BVDv to demonstrate how the herd-level sensitivity and specificity might be estimated on the basis 157 
of an interpretation of seroprevalence data collected from young stock in Scottish beef suckler 158 
herds. 159 
Relevant epidemiological attributes of BVDv 160 
A natural gold standard for defining a herd as BVDv positive is evidence of circulating virus in the 161 
herd and therefore evidence of the presence of at least one persistently or transiently infected 162 
animal in the herd, which might be detected on the basis of screening animals for virus or for BVDv 163 
antigens. Such screening would require a great deal of testing (of every or nearly every animal in a 164 
herd), and the consequences of a false negative result could be substantial. Alternatively, however, 165 
the epidemiology of BVD virus is such that the presence of BVD virus in the herd is amenable to 166 
screening by testing for antibodies in animals of any age, and particularly in young stock. A study 14 167 
found that the within-herd antibody seroprevalence from herds in which an antigen-positive animal 168 
was identified was 87% whilst it was only 43% in herds in which no antigen-positive animal was 169 
found. Therefore the within-herd prevalence of antibody-positive animals may be effectively used as 170 
a proxy or indicator for the presence or absence of antigen-positive animals.  171 
Optimising the number of animals to test and the cut-point value 172 
When a number of individual animals are tested for antibody in order to determine a binary (i.e., 173 
positive or negative) herd status, there are two important decisions to be made. The first is the 174 
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number of animals to be tested and the second is the cut-point for the number of positive animals at 175 
or above which the herd is deemed positive. Commonly the number of animals to be tested in BVDv 176 
eradication programmes is 5-10 young stock 5,9,15–17 although it has been suggested that as few as 177 
three young stock might need testing 17 especially if the antibody test is done in tandem with antigen 178 
testing 18. A BVDv eradication programme now being initiated in the Netherlands involves initial 179 
antibody spot-testing of five animals, with a cut-point for the number of antibody-positive animals of 180 
two.  One clear benefit of choosing a cut-point of two (as opposed to one) is that it reduces the risk 181 
of false positives and thus reduces the risk of unnecessary and expensive secondary testing of the 182 
whole herd. Our work informs decisions regarding sample numbers and threshold values under 183 
different conditions. 184 
The optimum threshold number, or cut-point, of antibody-positive animals for making a herd-level 185 
determination is dependent on the number of animals sampled. If ten animals are tested then the 186 
optimum cut-point appears to be greater than one (Figure 2). This matches recommendations 187 
published elsewhere 5,19. In our analysis the optimum appears to be two positive animals out of ten, 188 
if the intermediate seroprevalence group is considered positive and a cut-point of around seven 189 
positive animals if the intermediate seroprevalence group is considered to be negative (Figure 2). 190 
Whilst it appears justified from an epidemiological point of view, using a cut-point of greater than 191 
one may be counter-intuitive to farmers and veterinary practitioners. To use a cut-point of greater 192 
than one is to lose some sensitivity of the test but to gain specificity i.e. to reduce the probability of 193 
false positives. As discussed below, the best balance between sensitivity and specificity is dependent 194 
upon the stage of a disease eradication programme, as discussed below. 195 
Performance of the individual level test 196 
Our approach to estimating the group-level sensitivity and specificity is based on within-herd 197 
prevalence of antibody-positive animals, however it is worth noting that the individual tests are not 198 
perfect either. In the survey on which our simulations are based, the test used was Svanovir BVDV 199 
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antibody ELISA 20. This test is reported (by the manufacturer) to have a sensitivity and specificity of 200 
100% and 98.2% respectively in comparison to a virus neutralisation test. In our simulations we have 201 
used the sensitivity and specificity from the statistical distributions reported in the study8 on which 202 
our simulations are based. The sensitivity (and 95% confidence interval) is 96.3% (91.9%, 99.8%) and 203 
the specificity is 98.8% (98.0%, 99.3%). 204 
Our study is based on the categorisation of individual antibody scores into a binary positive or 205 
negative result by comparing the antibody scores with a cut-off. This is the conventional way of 206 
interpreting individual antibody results and is both convenient and easily interpreted. However, 207 
when we scale up to testing at the group level it is possible that the loss of information that is 208 
involved in categorising a continuous antibody score into a binary positive or negative is an 209 
important loss of information. For example, it is possible that having several calves with an antibody 210 
score just below the cut-off is a better predictor of a positive herd than having only one calf just 211 
above the cut-off. Current eradication schemes tend not to be set up to report individual antibody 212 
scores, and it is not known how frequently such a situation might occur. To take into account the 213 
individual antibody scores would require further investigation, ideally using data pertaining to 214 
individual antibody scores from sampled calves from herds with and without PI animals. The 215 
interpretation would require a multivariate analysis to optimally interpret several antibody scores 216 
without recourse to the binary categorisation. Such an approach might improve the herd-level test 217 
performance but might be unattractive to veterinary practitioners and to producers because it 218 
would involve complex and non-transparent calculations.  219 
 220 
The effect of herds characterised by intermediate within-herd antibody seroprevalence levels 221 
The extent to which antibody seroprevalence can be used to determine herd-level status of infection 222 
is dependent on the level of separation of the frequency distribution of seroprevalence values in 223 
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negative herds compared to the distribution in positive herds (see Figure 1). The greater the 224 
separation of these frequency distributions, the easier it is to observe separate groups or classes of 225 
herds (aka “components” in the statistical literature) within the overall distribution. Various 226 
statistical methods exist for identifying and describing such classes or groups in a frequency 227 
distribution. The results we present here are predicated on the empirical description of such classes 228 
from a randomised study of Scottish beef herds prior to the Scottish eradication scheme 8. The 229 
Scottish study found three classes, characterised by low, intermediate and high seroprevalence. Our 230 
analyses are based on the assumption that those groups represent different epidemiological herd 231 
statuses. The analyses are made complex by the fact that the epidemiological status of the group of 232 
herds characterised by intermediate levels of antibody seroprevalence is uncertain. Ideally we would 233 
have data from the same herds on both the within-herd seroprevalence for young stock and 234 
whether or not an infected animal exists in the herd. With such data we would be able to confidently 235 
describe the status of herds in the group with intermediate seroprevalence, but in the absence of 236 
such data we can consider the two extremes – i.e. that all herds in this group are either negative or 237 
positive. It is probable that this group of herds with intermediate seroprevalence consist of a mixture 238 
of truly positive and truly negative herds, in which case the correct interpretation would lie between 239 
the two extremes presented here. 240 
It is worth considering the wider evidence regarding the existence of a group of herds with 241 
intermediate seroprevalence levels. Other studies have presented data suggesting the possible 242 
existence of such a group 11,12. On the other hand at least one study exists in which there was no 243 
obvious middle component in the distribution of within-herd seroprevalence 5.  244 
There are various possible causes of intermediate seroprevalence in some herds: 245 
• Existence of residual maternal antibody derived from dams in young stock that have not, in 246 
fact, been exposed to the virus 247 
• The young stock have been vaccinated 248 
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• The young stock were exposed to low levels of virus (for example, over fence from a PI or 249 
transiently infected animal) leading to a low antibody response 250 
• Fomite contamination – leading to low antibody response and hence low prevalence 251 
• Exposure to a particular strain of virus that causes low antibody response 252 
• Heterogeneity in ages of the sampling group – if there are some new recruits to the group 253 
post-exposure they will be antibody negative and will “dilute” the group and hence reduce 254 
the prevalence 255 
In our analyses we have combined the intermediate seroprevalence group with either the low 256 
seroprevalence (negative) group or the high seroprevalence (positive) group. In doing so, we have 257 
effectively created a mixture of two, rather than three, groups. The resulting mixture depends upon 258 
the relative proportional contribution each group gives and we have, implicitly, used the relative 259 
proportions outlined in the original description of the three groups (Figure 1). It is likely the 260 
contribution that the intermediate seroprevalence group makes to the overall distribution is not 261 
constant across time or between countries.  It is not clear, however, whether we can predict how its 262 
contribution will vary. For example, in the case of a country or region with an eradication scheme 263 
such as that in Scotland, it is possible to envisage either an increase or decrease in the proportion of 264 
herds that fall into the intermediate seroprevalence category. During an eradication scheme, if all 265 
goes well, there is “movement” of herds from the right hand end of the seroprevalence frequency 266 
distribution (Figure 1) towards the left hand end of the distribution. Therefore it is not possible to 267 
predict whether the middle group will gain more from the high seroprevalence group than it loses to 268 
the low seroprevalence group. 269 
Consequences of misunderstanding the status of the intermediate seroprevalence group 270 
The large differences in herd-level test characteristics such as sensitivity, specificity, false negative 271 
and false positive rates, depending on whether the intermediate seroprevalence group is assumed 272 
to be negative or positive (Figures  2, 3, 4; Tables 1 & 2) highlight the importance of better 273 
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understanding this group’s epidemiological status if we wish to improve the accuracy of our 274 
estimates of these test characteristics. For example, in Figure 2, it appears that, for a sample size of 275 
ten young stock, the trade-off between herd-level sensitivity and specificity is optimal with a cut-276 
point of two if the middle component is positive but it is a cut-point of six or seven if the middle 277 
component is negative. Therefore the consequence of misunderstanding the status of the 278 
intermediate seroprevalence group is large – and in particular may lead to poor selection of the 279 
number of animals to test and poor selection of cut-points. 280 
It is also worth noting that whatever the true status of intermediate seroprevalence group, the 281 
assumption that it represents truly positive herds results in estimates of the herd-level sensitivity 282 
which are lower than, or equal to, the actual herd-level sensitivity: this then represents a “worse 283 
case” estimate of herd-level sensitivity. It is therefore a “conservative” estimate for herd-level 284 
sensitivity.  If this group were composed either partly or wholly of truly negative herds, then the 285 
actual herd-level sensitivity would be higher than predicted on the basis of the assumption that they 286 
are all truly positive. The opposite relationship can be seen for herd-level specificity: assuming that 287 
the intermediate seroprevalence group is positive results in estimates for this parameter which 288 
might be higher than the actual value. Whether it is preferable to under-estimate herd-level 289 
sensitivity or specificity of a test may be dependent on other conditions, as discussed below.  Which 290 
of these test characteristics (sensitivity or specificity) is more important may determine which 291 
assumption, regarding the intermediate prevalence group, is the more “conservative” or risk-averse 292 
at a particular time.  293 
The final stages of an eradication scheme 294 
We may also consider the relative importance of herd-level sensitivity and specificity towards the 295 
end of an eradication scheme when the prevalence is low compared to the early stages of an 296 
eradication scheme when the prevalence is high. In these latter stages of an eradication scheme it 297 
becomes more important that positive herds are accurately identified than it is in the early stages 298 
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when it is typically accepted (and is less consequential) that some positive herds may be incorrectly 299 
classified as negative. This is because as the population approaches total susceptibility, the 300 
epidemiological, economic and political consequences of reintroduction become substantial 6. 301 
Therefore it is important that the test sensitivity is particularly high during the final stages of 302 
eradication even if this comes with the increased risk of false positives. To achieve a meaningful and 303 
maximum sensitivity indicates a cut-point of just one antibody positive animal. Thus the overall 304 
probability of a false negative is reduced if the number of animals tested is increased to ten and the 305 
cut-point is held at one (Figures 2, 3). The consequent high risk of false positives due to the low 306 
specificity (Figure 2 and Table 2) will require diplomatic explanations to farmers and veterinary 307 
practitioners. Specifically the explanation needed is that an initial positive result requires 308 
subsequent testing before the result is accepted as genuinely positive. Typically this subsequent test 309 
could be a full herd antigen screening for PI animals. Such a two-stage process in response to an 310 
initial positive result is a reasonable way of screening a herd before declaring its status. The 311 
proposed scheme in the Netherlands is based on follow up tests if the number of positive animals is 312 
equal to or higher than the cut-point (which is two out of five young stock in this example). 313 
  314 
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Conclusions 315 
In conclusion, we find that: 316 
• The true status of the intermediate seroprevalence group is crucial, and analyses of herd-317 
level sensitivity and specificity are highly dependent on the assumed status of this group. 318 
Misunderstanding the true status of this group will lead to imperfect design of a screening 319 
scheme and in particular poor selection of cut-points; 320 
• Reducing the number of young stock screened for BVDv antibody from ten to five need not 321 
result in a substantial drop in herd-level sensitivity and specificity if the appropriate cut-322 
point is selected; 323 
• Increasing the cut-point to a value greater than one for the number of antibody seropositive 324 
animals before treating a herd as positive may be useful at the outset of an eradication 325 
scheme; The benefit of doing so is to increase the specificity, and reduce the cost of 326 
unnecessary secondary whole herd screening that is associated with a false positive. 327 
• Increasing the number of animals tested, reducing the cut-point to one, or adopting both 328 
actions in the latter stages of an eradication scheme is warranted in order to maximise the 329 
herd-level sensitivity and thus reduce the number of false negative herds to as great an 330 
extent possible. 331 
We believe this paper provides a useful example of a framework for understanding the complexity of 332 
measuring herd exposure to an infectious agent using a spot-test approach. It enables us to consider 333 
how the ‘test’ should evolve over the course of an eradication scheme.  334 
 335 
  336 
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Methods 337 
We estimated the herd-level sensitivity and specificity of a spot test of young stock using the 338 
frequency distribution of the number of BVD antibody-positive animals within a sample of young 339 
stock from Scottish beef suckler herds. Our starting point was the modelled distribution of a mixture 340 
of components for the number of positive ELISA antibody tests out of ten as published by Brülisauer 341 
et al. 8  identified and described three statistically distinct groups or classes of herds on the basis of 342 
their within-herd seroprevalence levels: these groups are characterised by low, intermediate and 343 
high antibody seroprevalences.  Brülisauer et al. (2010)8 described these groups statistically thus 344 
making them amenable to simulation (Figure 1).    345 
We hypothesised that each group reflects an epidemiologically important class of herd with the 346 
group characterised by low seroprevalences reflecting negative status herds and the group with high 347 
seroprevalences reflecting positive status herds. The status of herds with intermediate 348 
seroprevalences remains unclear and has several possible explanations8,11,12 (see Discussion above). 349 
We explore here the consequences of both the extreme scenarios that this intermediate group is 350 
fully negative or fully positive whilst recognising that it could be a mixture of both negative and 351 
positive herds. 352 
We then envisaged the relatively high herd-level prevalence which might be expected at the outset 353 
of an eradication scheme and compared it with the relatively low prevalence anticipated in the latter 354 
stages. We sought to demonstrate the varying rate of false negatives, false positives and predictive 355 
values dependent on the prevalence as well as the screening design. 356 
The simulation was carried out using the following procedure which is also illustrated in a flow 357 
diagram (Figure 6). 358 
The simulated population 359 
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We constructed a population of 2000 simulated herds (we chose 2000 because this is the 360 
approximate number of suckler herds in the sampling frame of Scottish population originally 361 
studied), which were distributed among the three classes of herds described above (i.e., herd classes 362 
characterised by low, intermediate, and high antibody seroprevalence levels within groups of young 363 
stock). The proportion of herds in each class was simulated based on published data 8.  We then 364 
simulated the true antibody seroprevalence in young stock within each herd (i.e., the overall 365 
proportion of young animals in each herd that are truly antibody positive), based on the range of 366 
seroprevalence values reported for the class of each herd.  All simulation parameter values were 367 
based on published estimates, as presented in Table 3. 368 
Testing for antibodies to BVDv 369 
From each simulated herd, a sample of a fixed number of animals was drawn (the exact sample size 370 
varied depending on the scenario: see below for more detail).  No assumption for the total number 371 
of young stock in the herd was made as this was not necessary – it was merely assumed that each 372 
herd had sufficient young stock to fulfil the desired sample. The true status (antibody-positive or 373 
antibody-negative) of each animal in the sample was determined based on a random binomial 374 
distribution defined by the overall proportion of antibody-positive animals in the herd.  The test 375 
status of each animal in the sample was then determined on the basis of its true status and the 376 
(imperfect) test performance parameters (test sensitivity and specificity at the individual-animal 377 
level) drawn from the triangular distributions described in Table 3. 378 
Herd-level status determination 379 
We then envisaged a cut-point for the number of test-positive animals in the sample at, or above 380 
which, the sampled herd would be deemed to be positive. If the number of test positives was below 381 
that cut-point then the herd was interpreted as being negative.  382 
Calculating herd-level sensitivity and specificity 383 
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Therefore, we had 2000 herds each of which was from one of the three classes of herd 384 
(characterised by low, intermediate or high antibody seroprevalence). The low-seroprevalence class 385 
of herd was described as negative, and the high-seroprevalence as positive. The intermediate 386 
seroprevalence group of herd was treated as either negative or positive depending on which 387 
scenario we selected. This status was, in effect, our (simulated) “true” status for the herd. For each 388 
herd we also had the number of individual test-positive animals, and therefore when compared to a 389 
chosen cut-point the herd was designated “test positive” or “test negative”. As the test is not 390 
perfect, some herds may be truly negative but test-positive and vice versa. By summing over all 391 
herds we then calculated the proportion of “true” positive herds that tested positive and similarly 392 
for negative herds to estimate the herd-level sensitivity and specificity of the screening regimen. 393 
Herd-level specificity and sensitivity under different scenarios 394 
Different scenarios were examined to explore the consequences of important contributing factors 395 
on the predicted herd-level specificity and sensitivity:  396 
• Different sample sizes (the number of young stock tested); 397 
• Different cut-points; and 398 
• Different assumptions about the group of herds characterised by intermediate 399 
seroprevalence. 400 
False negative, false positive rates and predictive values 401 
The resulting simulated herd-level sensitivity and specificity estimates were used to estimate rates of 402 
false negatives and false positives and to estimate positive and negative predictive values under two 403 
different scenarios: a) high BVDv prevalence as typical of the early stages for an eradication scheme 404 
and b) low BVDv prevalence as typical of an “end-game” scenario towards the latter stages of an 405 
eradication scheme. The high BVDv herd-level prevalence was set at 60% 8,21–23. The low BVDv herd-406 
20 
 
level prevalence scenario was hypothesised at 0.5% based on work by Løken and Nyberg (2013) 24 in 407 
which after 7 years of eradication the prevalence had dropped to 0.5%. 408 
Simulating  uncertainty 409 
Each run of the model provided a single estimate of the herd-level sensitivity and specificity, based 410 
on 2000 herds. In order to estimate the variation or uncertainty, we ran the model 2000 times (to 411 
provide a 95% precision of ± 0.5% on a proportion of 1%), thus giving a range of values for herd-level 412 
sensitivity and specificity. 413 
  414 
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Tables 497 
Table 1. Median (& 95% percentile) herd-level sensitivity, specificity, false negative rate amongst 498 
positive herds and false positive rate amongst negative herds based on five animals and a cut-point 499 
of two seropositive animals (as written into the Netherlands’ eradication programme). 500 
 If herds with intermediate 
within-herd seroprevalence are 
treated as positive 
If herds with intermediate 
within-herd seroprevalence are 
treated as negative 
Sensitivity 75% (66%, 83%) 100% (99.6%, 100%)
False negative rate amongst 
pos herds 25% (17%, 34%) 0% (0%, 0.4%) 
   
Specificity 99.9% (99.4%, 100%) 90% (86%, 94%) 
False positive rate amongst 
neg herds 0.10% (0%, 0.5%) 10% (6%, 14%) 
 501 
  502 
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Table 2. Overall probability of false negatives and positives based on a sample size of five young stock and the comparing the cut-point of two seropositive 503 
animals to one seropositive animal. 504 
    
If herds with intermediate within-herd 
seroprevalence are treated as positive 
If herds with intermediate within-herd 
seroprevalence are treated as negative 
  Cut-point number of 
positive animals 
 
1/5 
 
2/5 
 
1/5 
 
2/5 
 
High herd-level 
prevalence (60% of 
herds) 
Overall Probability of 
False neg 
 
4.5% 
(2.4%, 7.4%) 
15% 
(10%, 21%) 
0% 
(0%, 0%) 
0% 
(0%, 0.2%%) 
 
Overall Probability of 
False pos 
 
2.6% 
(1.3%, 3.9%) 
0.06% 
(0%, 0.21%) 
8.67% 
(6.46%, 10.66%)  
3.92% 
(2.55%, 5.59%)) 
 
Positive predictive 
value 
 
95.5% 
(93.3%, 97.7%) 
99.87% 
(99.5%, 100%) 
87.4% 
(84.9%, 90.3%) 
93.87% 
(91.47%, 95.92%) 
 
Negative predictive 
value 
 
89.26% 
(83.51%, 93.98%) 
72.67% 
(65.86%, 79.53%) 
100.00% 
(100.00%, 100.00%) 
100.00% 
(99.33%, 100.00%) 
Low herd-level 
prevalence (5% of 
herds) 
Overall Probability of 
False neg 
 
0.04% 
(0.02%, 0.06%) 
0.1% 
(0.09%, 0.17%) 
0.00% 
(0%, 0%) 
0.00% 
(0%, 0.002%) 
 
Overall Probability of 
False pos 
 
6.5% 
(3.3%, 9.8%) 
0.1% 
(0%, 0.52%) 
21.57% 
(16.08%, 26.51%) 
9.74% 
(6.34%, 13.90%) 
 
Positive predictive 
value 
 
6.64% 
(4.47%, 12.29%) 
71.25% 
(41.58%, 100.00%) 
2.27% 
(1.85%, 3.02%) 
4.88% 
(3.47%, 7.31%) 
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 Negative predictive value 
99.96% 
(99.93%, 99.98%) 
99.87% 
(99.83%, 99.91%) 
99.96% 
(99.94%, 99.98%) 
100.00% 
(100.00%, 100.00%) 
 505 
29 
 
Table 3. The parameters and their 95% credible intervals from 8, and consequent triangular 506 
distributions 25used to simulate the number of true positives and the number of test positives (see 507 
Supplementary Information for more detail). 508 
Parameter Published 95% 
Credible Interval 
Triangular distribution (min, 
mode, max) 
π1 The proportion of herds characterised by 
low within-herd seroprevalence 
(0.623, 0.742) 0.606, 0.683, 0.759 
 
π2  The  proportion of herds characterised 
by intermediate within-herd 
seroprevalence 
(0.113, 0.213) 0.099, 0.163, 0.227 
 
π3 The proportion of herds characterised by 
high within-herd seroprevalence 
(0.116, 0.197) 0.104, 0.157, 0.209 
 
µ1 The within-herd seroprevalence for 
herds with low seroprevalence 
(0,0) NA
µ2 The within-herd seroprevalence for  
herds with intermediate seroprevalence 
(0.263, 0.385) 0.245, 0.324, 0.403 
 
µ3 The within-herd seroprevalence for 
herds with high seroprevalence 
(0.919, 0.998) 0.908, 0.959, 1.000 
 
Se The sensitivity of the individual (animal-
level) test for BVDv antibody 
(0.919, 0.998) 0.908, 0.959, 1.000 
Sp The specificity of the individual (animal-
level) test for BVDv antibody 
(0.980, 0.993) 0.978, 0.987, 0.995 
 
 509 
  510 
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Figure legends 511 
Figure 1. A graphical presentation of the three  groups of herds identified and described on the basis 512 
of different levels of antibody seroprevalence in a study involving seroprevalence of ten young stock 513 
from Scottish beef suckler herds 8 514 
Figure 2. The herd-level test performance (sensitivity in black, specificity in red) where the group of 515 
herds with intermediate within-herd seroprevalence is treated as either positive or negative and 516 
using a sample size of either five or ten animals.  517 
Figure 3. The median overall probability of false negatives with a cut-point of two positive animals 518 
and if herds with intermediate within-herd seroprevalence are treated as is positive. 519 
Figure 4. The median overall probability of false negatives with a cut-point of one positive animal 520 
and if the herds with intermediate within-herd seroprevalence are treated as positive. 521 
Figure 5. The median overall probability of false negatives as a function of the number of animals 522 
tested, two different prevalence levels (60% and 0.5%) and cut-points of one and two positive 523 
animals. 524 
Figure 6. Flow diagram representing the process by which herd-level sensitivity and specificity (and 525 
uncertainty around these) was generated using the published estimates for animal-level antibody 526 
seroprevalence and test performance for each of the components identified in the source paper8  527 






